Craig Lee Slingluff

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Victor H Engelhard · 1 shared grant, 2021 · strength 0.56
   • Grant Cancer Therapeutics Program (CRX) P30CA044579↗
2. Todd W. Bauer · 5 shared papers, 2016–2024 · strength 0.54
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
   • Paper From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. DOI 10.1186/s40425-016-0119-z↗
3. Osama E. Rahma · 4 shared papers, 2015–2024 · strength 0.44
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
   • Paper From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. DOI 10.1186/s40425-016-0119-z↗
4. Matthew H. G. Katz · 3 shared papers, 2015–2024 · strength 0.36
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
   • Paper A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combin… DOI 10.1186/2051-1426-3-s2-p167↗
5. Victoire Cardot‐Ruffino · 2 shared papers, 2023–2024 · strength 0.30
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
6. Andressa Dias Costa · 2 shared papers, 2023–2024 · strength 0.30
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
7. Chee‐Chee Stucky · 2 shared papers, 2023–2024 · strength 0.30
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
8. Rawad Elias · 2 shared papers, 2023–2024 · strength 0.30
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
9. Matthew J. Reilley · 2 shared papers, 2023–2024 · strength 0.30
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
10. Nipun B. Merchant · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
11. Brian Matthew Wolpin · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
12. Tanios Bekaii‐Saab · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
13. Jonathan Andrew Nowak · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
14. Stephanie K. Dougan · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
15. Timothy N. J. Bullock · 3 shared papers, 2015–2018 · strength 0.20
    • Paper Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. DOI 10.18632/oncotarget.23944↗
    • Paper CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-17-2283↗
    • Paper A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combin… DOI 10.1186/2051-1426-3-s2-p167↗
16. Gauri Rajani Varadhachary · 2 shared papers, 2015–2023 · strength 0.19
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
    • Paper A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combin… DOI 10.1186/2051-1426-3-s2-p167↗
17. Thomas E. Clancy · 1 shared paper, 2024 · strength 0.16
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
18. Jiping Wang · 1 shared paper, 2024 · strength 0.16
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
19. Lestat R. Ali · 1 shared paper, 2024 · strength 0.16
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
20. Thomas Adam Abrams · 1 shared paper, 2024 · strength 0.16
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
21. Joseph Douglas Mancias · 1 shared paper, 2024 · strength 0.16
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
22. Paul Raymond Kunk · 1 shared paper, 2016 · strength 0.08
    • Paper From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. DOI 10.1186/s40425-016-0119-z↗
23. Kiley L. Anderson-Knapp · 1 shared paper, 2018 · strength 0.08
    • Paper Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. DOI 10.18632/oncotarget.23944↗
24. John C. Herr · 1 shared paper, 2018 · strength 0.08
    • Paper Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. DOI 10.18632/oncotarget.23944↗
25. Alex D. Michaels · 1 shared paper, 2018 · strength 0.07
    • Paper CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. DOI 10.1158/1078-0432.ccr-17-2283↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.